Lynthera Corp

Lancaster, PA

UEI
EHB9K3ECWV79
CAGE
79RQ5
Primary NAICS
Not on record
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • For Profit Organization
  • Asian-Pacific American Owned
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1200 Corporate Blvd #10c, Lancaster, PA 17601, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Novel formulation technology for the sustained release naloxone to improve outcomes in the management of opioid overdose R43DA058477 National Institute on Drug Abuse (NIH) $695,000
Drug delivery platform for ocular allergy therapy R44EY033611 National Eye Institute (NIH) $1,800,006
Drug delivery platform for ocular allergy therapy R43EY033611 National Eye Institute (NIH) $600,000
Sustained delivery technology for cyclosporine a in the treatment of autoimmune response R44EY032424 National Eye Institute (NIH) $2,385,000
Sustained delivery technology for cyclosporine a in the treatment of autoimmune response R43EY032424 National Eye Institute (NIH) $900,000

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

Vendor Location Primary NAICS
Medchem Partners LLC UEI S93ZFQLD4ZC7 Lexington, MA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Consegna Pharma Inc. UEI NU7SAKDR52N8 Pittsburgh, PA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Human Cell Co UEI F4N9XZWABV33 Naperville, IL —
Nanoscope Technologies LLC UEI H6DNZXT5MMT1 Bedford, TX 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Coruna Medical Inc. UEI JWDAJJYZRG53 Longmont, CO 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Lynthera Corp is a minority-owned, for-profit small business that provides research and development services related to drug delivery technologies, particularly for ophthalmic applications. Through federal grants from the National Institutes of Health, the company has developed sustained-release formulations and drug-eluting contact lens platforms to better treat conditions like opioid overdose, ocular allergies, and dry eye disease.

Specifically, Lynthera Corp has received project grants to formulate a subcutaneous hydrogel containing naloxone nanoparticles for opioid overdose management, funded by the National Institute on Drug Abuse. They also developed ketotifen and olopatadine releasing contact lenses for allergic conjunctivitis under a National Eye Institute grant. Additionally, the company designed a cyclosporine-eluting contact lens using nanocarriers to improve treatment of inflammatory dry eye disease, also supported by the National Eye Institute. Across these awards, Lynthera Corp serves as the prime recipient conducting the research and development internally. The goods and services provided are proprietary technologies and drug delivery platforms resulting from the grant-funded research.

Quick answers

Is Lynthera Corp registered in SAM.gov?

Yes. Lynthera Corp's SAM.gov registration is active through January 1, 2027.

What is Lynthera Corp's most recent federal award?

Lynthera Corp's most recent federal grant award is Novel formulation technology for the sustained release naloxone to improve outcomes in the management of opioid overdose (R43DA058477), from National Institute on Drug Abuse (NIH), on September 15, 2023.

On GovTribe

See Lynthera Corp's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login